N S Shulman

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients
    Amit Kapoor
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Retrovirology 5:7. 2008
  2. ncbi request reprint Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
    N S Shulman
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    J Acquir Immune Defic Syndr 27:377-80. 2001
  3. ncbi request reprint Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients
    Nancy S Shulman
    Stanford University School of Medicine, California 94305, USA
    J Acquir Immune Defic Syndr 31:121-7. 2002
  4. pmc Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
    Nancy Shulman
    Stanford University School of Medicine, California, USA
    Antimicrob Agents Chemother 46:3907-16. 2002
  5. ncbi request reprint A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors
    Nancy Shulman
    Division of Infectious Diseases, Stanford University, 300 Pasteur Drive, room S 156, Stanford, CA 94305, USA
    Curr Drug Targets Infect Disord 3:273-81. 2003
  6. ncbi request reprint Genetic correlates of efavirenz hypersusceptibility
    Nancy S Shulman
    Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
    AIDS 18:1781-5. 2004
  7. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays
    Nancy S Shulman
    Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA
    J Acquir Immune Defic Syndr 39:78-81. 2005
  8. ncbi request reprint Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
    N S Shulman
    Stanford University School of Medicine, Division of Infectious Diseases, California 94305, USA
    J Acquir Immune Defic Syndr 23:221-6. 2000
  9. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
  10. pmc Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques
    Mark A Winters
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    Antimicrob Agents Chemother 54:4059-63. 2010

Research Grants

Collaborators

Detail Information

Publications15

  1. pmc Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients
    Amit Kapoor
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Retrovirology 5:7. 2008
    ....
  2. ncbi request reprint Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
    N S Shulman
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    J Acquir Immune Defic Syndr 27:377-80. 2001
    ..We conclude that in patients with prior ZDV treatment, those with only one ZDV mutation, particularly at position 70, can still get reasonable virologic activity from d4T. Those with more mutations are not likely to have much benefit...
  3. ncbi request reprint Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients
    Nancy S Shulman
    Stanford University School of Medicine, California 94305, USA
    J Acquir Immune Defic Syndr 31:121-7. 2002
    ..d4T susceptibility greater than 1.4-fold change was associated with failure to achieve significant viral load reduction after 8 weeks of d4T monotherapy...
  4. pmc Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
    Nancy Shulman
    Stanford University School of Medicine, California, USA
    Antimicrob Agents Chemother 46:3907-16. 2002
    ..The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response...
  5. ncbi request reprint A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors
    Nancy Shulman
    Division of Infectious Diseases, Stanford University, 300 Pasteur Drive, room S 156, Stanford, CA 94305, USA
    Curr Drug Targets Infect Disord 3:273-81. 2003
    ....
  6. ncbi request reprint Genetic correlates of efavirenz hypersusceptibility
    Nancy S Shulman
    Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA
    AIDS 18:1781-5. 2004
    ..NNRTI hypersusceptibility has been associated with improved outcomes to NNRTI-based therapy...
  7. ncbi request reprint Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays
    Nancy S Shulman
    Center for AIDS Research, Division of Infectious Diseases, Stanford University, Stanford, CA 97305, USA
    J Acquir Immune Defic Syndr 39:78-81. 2005
    ..In fact, there was a report that a commercial multicycle assay did not readily detect hypersusceptibility...
  8. ncbi request reprint Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
    N S Shulman
    Stanford University School of Medicine, Division of Infectious Diseases, California 94305, USA
    J Acquir Immune Defic Syndr 23:221-6. 2000
    ..To determine the impact of prior nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy, genotypic resistance, and other variables on response to efavirenz (EFV)- and adefovir dipivoxil (ADV)-based salvage therapy...
  9. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
    ..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
  10. pmc Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques
    Mark A Winters
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, California 94304, USA
    Antimicrob Agents Chemother 54:4059-63. 2010
    ..The low concentrations of fetal maraviroc and short pharmacokinetic profile in infants suggest that a single maternal intrapartum dose of maraviroc would not be effective in reducing the risk of MTCT of HIV...
  11. pmc Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients
    Severine Margeridon-Thermet
    Department of Medicine, Stanford University, Stanford, CA, USA
    J Infect Dis 199:1275-85. 2009
    ..UDPS detected low-prevalence HBV variants with NRTI-resistance mutations, G-to-A hypermutation, and low-level dual genotype infection with a sensitivity not previously possible...
  12. ncbi request reprint Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors
    Shauna A Clark
    School of Medicine, University of Pittsburgh, 3550 Terrace Street, Pittsburgh, PA 15261, USA
    AIDS 20:981-4. 2006
    ....
  13. ncbi request reprint More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175
    Nancy S Shulman
    J Infect Dis 196:328-9; author reply 329-30. 2007
  14. ncbi request reprint Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance
    Joel E Gallant
    The Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 8:489-506. 2003
    ..This review summarizes research advances that further the understanding of nucleoside and nucleotide analogue resistance mutations, and their interplay...
  15. ncbi request reprint Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine
    Denise Lecossier
    INSERM U552, Hopital Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:37-42. 2005
    ..These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens...

Research Grants2

  1. Non-nucleoside Reverse Transcriptive Hypersensitivity
    Nancy Shulman; Fiscal Year: 2006
    ....